SCM
ASBP

Shaolin Capital Management’s Aspire Biopharma ASBP Stock Holding History

Shaolin Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-53
Closed -$689K – 397
2023
Q4 		$689K Sell
53
-16
-23% -$210K 0.02% 167
2023
Q3 		$902K Buy
+69
New +$890K 0.03% 200
2023
Q2 		– Sell
-250
Closed -$3.15M – 725
2023
Q1 		$3.15M Hold
250
– – 0.09% 186
2022
Q4 		$3.09M Buy
250
+42
+20% +$514K 0.09% 253
2022
Q3 		$2.54M Buy
+208
New +$2.51M 0.07% 322

Other funds holding ASBP

FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Shaolin Capital Management's ASBP Position: Q1 2024 in Review

Shaolin Capital Management sold out of Aspire Biopharma (ASBP) in Q1 2024, closing a stake of 53 shares — an estimated $689K sold.

Shaolin Capital Management first reported a position in ASBP in Q3 2022 and held it in 5 quarters. The position peaked at $3.15M in Q1 2023. 17 funds tracked by Wall St. Rank hold ASBP as of Q1 2024.

  • Shaolin Capital Management reported no remaining Aspire Biopharma position as of Q1 2024 after selling out during the quarter.
  • Shaolin Capital Management sold 53 Aspire Biopharma shares in Q1 2024, an estimated $689K.
  • Shaolin Capital Management first reported a position in Aspire Biopharma in Q3 2022 and held it in 5 quarters.
  • Shaolin Capital Management's Aspire Biopharma position peaked at $3.15M in Q1 2023.
  • 17 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2024.

Based on Shaolin Capital Management's 13F filing for Q1 2024, filed 15 May 2024.